Article
Increasing HPV Vaccination Coverage to Prevent Oropharyngeal Cancer: A Cost-effectiveness Analysis
Tumor Virus Research
(2022)
Abstract
The incidence of oropharyngeal cancer (OPC) has been rising, especially among middle-aged men. While Human Papillomavirus (HPV) has been irrevocably implicated in the pathogenesis of oropharyngeal cancer (OPC), the current HPV vaccination uptake rate remains low in the US. The aim of our study was to evaluate the impact of increased HPV vaccination coverage on HPV-associated OPC incidence and costs. A decision analytic model was constructed for hypothetical cohorts of 9-year-old boys and girls. Two strategies were compared: 1) Maintaining the current vaccination uptake rates; 2) Increasing HPV vaccination uptake rates to the Healthy People 2030 target (80%) for both sexes. Increasing HPV vaccination coverage rates to 80% would be expected to prevent 5,339 OPC cases at a cost of $0.57 billion USD. Increased HPV vaccination coverage would result in 7,430 quality-adjusted life year (QALY) gains in the overall population, and it is estimated to be cost-effective for males with an incremental cost-effectiveness ratio of $86,940 per QALY gained under certain conditions. Expanding HPV vaccination rates would likely provide a cost-effective way to reduce the OPC incidence, particularly among males.
Keywords
- HPV Vaccination,
- Coverage,
- Prevent,
- Oropharyngeal Cancer,
- Analysis
Disciplines
Publication Date
June, 2022
DOI
10.1016/j.tvr.2021.200234
Citation Information
Alessandro Villa, S. E. Choi, A. Choudhary, J. Huang, et al.. "Increasing HPV Vaccination Coverage to Prevent Oropharyngeal Cancer: A Cost-effectiveness Analysis" Tumor Virus Research Vol. 13 (2022) p. 200234 ISSN: 2666-6790 Available at: http://works.bepress.com/alessandro-villa/13/